Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma: Drug showed reduced risk of disease or death and significantly improved progression-free survival
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52%…